Mark J. Rosenblum's Insider Trades & SAST Disclosures
Mark J. Rosenblum's most recent trade in Salarius Pharmaceuticals Inc was a trade of 22,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark J. Rosenblum.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 22,500 | 22,500 | - | - | Stock Option (right to buy) | |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 6,432 | 21,851 (0%) | 0% | 0 | Common Stock | |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 8,000 | 15,419 (0%) | 0% | 0 | Common Stock | |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 1.73 per share. | 03 Nov 2022 | 7,314 | 13,245 (0%) | 0% | 1.7 | 12,682 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 1.73 per share. | 03 Nov 2022 | 1,488 | 7,419 (0%) | 0% | 1.7 | 2,580 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Purchase of securities on an exchange or from another person at price $ 0.18 per share. | 31 May 2022 | 28,000 | 148,319 (1%) | 0% | 0.2 | 5,040 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.19 per share. | 03 May 2022 | 10,000 | 120,319 (0%) | 0% | 0.2 | 1,863 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Purchase of securities on an exchange or from another person at price $ 0.39 per share. | 03 Mar 2022 | 76,246 | 110,319 (0%) | 0% | 0.4 | 29,812 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.72 per share. | 03 Nov 2021 | 7,787 | 34,073 (0%) | 0% | 0.7 | 5,591 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.57 per share. | 03 May 2021 | 9,563 | 26,286 (0%) | 0% | 0.6 | 5,422 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.56 per share. | 03 Nov 2020 | 4,723 | 16,723 (0%) | 0% | 0.6 | 2,650 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 17 Aug 2020 | 5,000 | 12,000 (0%) | 0% | 1 | 5,000 | Common Stock |
| Salarius Pharmaceuticals Inc | Mark J. Rosenblum | Exec VP Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 49,955 | 49,955 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges